Comparison · NCT05397470-257dc342
Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Vital Parameters
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Vital Parameters. Trial comparisons, record NCT05397470-257dc342. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05397470-257dc342
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0287 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0287 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0287 | 0.0287 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part A: Losmapimod 15 Milligrams (mg) | Participants received Losmapimod 15 mg orally twice daily (BID) with food for 48 weeks. | 0 | 130 | OG000 |
| Group 2 | Part A: Placebo | Participants received matching placebo orally twice daily (BID) with food for 48 weeks. | 0 | 130 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part A: Number of Participants With Clinically Significant Changes in Vital Parameters
- Description
Vital parameters including pulse rate, respiration rate, blood pressure, and temperature were measured in seated or recumbent for at least 5 minutes. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
- Time frame
- Up to Week 48
- Population
- Safety Analysis Set.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
- NCT number
- NCT05397470
- Phases
- PHASE3
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod, Placebo oral tablet
- Lead sponsor
- Fulcrum Therapeutics
- Results first posted
- 2025-11-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05397470?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05397470-257dc342